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Abstract
In the twenty-first century, metabolomics allowed evaluating the profile of 
metabolites of various classes of compounds in the human body. The most impor-
tant achievement of the metabolic approach is to obtain evidence of the intersection 
of human biochemical pathways and its microbiota. The effect of certain microbial 
metabolites on the work of key enzymes involved in the biotransformation of amino 
acids and other substances becomes more important in patients at risk of develop-
ing neurological and mental disorders and also contributes to the development of 
life-threatening conditions up to multiple organ failure after operations, injuries, 
and serious diseases. The authors of this chapter call the microbiota an “invisible 
organ,” emphasizing its functional significance, and not just taxonomy, as previ-
ously thought. This chapter will discuss the mutually beneficial integration of the 
metabolome/microbiome in the body of healthy people and will focus on the effects 
of microbiota dysfunction.
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1. Introduction
Homeostasis is key for the normal performance of a human body. Many param-
eters are constantly maintained in fairly narrow vital ranges, such as temperature, 
acidity in the intracellular and intercellular spaces, the electrolyte concentrations, 
hormones, vitamins, etc. The traditional view is that the body itself is able to main-
tain the constancy of its internal environment due to a complex system of feedback 
(Figure 1). Each organ helps to maintain homeostasis, ensuring its specific func-
tion. It acts as a backward force that returns the system to equilibrium in the event 
of deviations from the normal state. Аlong with other organs, the microbiota plays 
an important role in maintaining homeostasis, despite being an “invisible organ.”
By the way, in terms of weight, the microbiota should be attributed to the largest 
organ that can be compared only with the brain or liver: this can be easily ascer-
tained using simple calculations based on known facts about the weight of human 
organs relative to the body weight of an adult (Figure 2). The human microbiota, 
which is a community of gut microorganisms, can be considered as an independent 
organ with many functions.
Metabolomics - New Insights into Biology and Medicine
2
In the twenty-first century, a new insight on the processes occurring in the 
human body in health and disease on the basis of the new knowledge of the micro-
biota is formed. Detection and identification of the trillions of bacteria that form 
the microbiota of healthy and sick people are made possible by the use of modern 
technologies, for example, sequencing of the 16S rRNA gene.
Metabolite-based approaches (or metabolomics) to the study of the human micro-
biota are more significant progress in biology and medicine, searching for answers 
to the question “What are the chemical and pathophysiological results of the 
metabolic activity of the microbiota?” Today many research teams are searching for 
answers to this question [1].
The host organism is a habitat for the microbiota, so maintaining homeostasis is 
vital for the survival of hundreds of bacterial species. The microbiota seeks to restore 
homeostasis in the case of minor metabolic disorders that are not systemic in nature, 
and it has a huge amount of possibilities for this. If changes in the vital functions 
Figure 1. 
Diagram of the interaction of organs that support the state of homeostasis.
Figure 2. 
Microbiota as a big but “invisible organ,” % of body mass compared to other vital organs in an adult weighing 
70 kg.
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of the body are serious, a new quality (pathology) is formed, the microbiota is also 
radically rebuilt: this is manifested not only in changes in the species composition of 
bacteria (taxonomy) but also in metabolic processes. Other non-normal products of 
microbial metabolism from the intestines enter the systemic circulation, and they 
can interfere with the endogenous metabolic pathways. When the microbiota works 
against the host, it is manifested by diseases, even death (sepsis).
The medical community has not yet formed an understanding of the role of 
the microbiota as a separate organ. A search query (“microbiota as an organ”) or 
(“microbiome as an organ”) in specialized databases, such as the Web of Science, 
Scopus, and Pubmed, gives a negative result. At the same time, a number of review 
articles are actually present which describe in detail the physiology and biochem-
istry of the close interaction of the intestinal microbiota with the host organism, in 
which there are many qualities and attributes of the organ.
This chapter formulates ideas about the microbiota as an organ, which has 
become possible due to the results of studies with metabolomic equipment of recent 
years. The material presented in this chapter relies primarily on articles published 
after 2010. Specialists working in both fundamental and clinical medicine are 
undoubtedly interested in the growing information about the role of microbiota 
in maintaining homeostasis, as well as the participation of microorganisms of the 
human body in the metabolic pathways, which are directly related to the develop-
ment of various pathologies.
2. Microbiota in a healthy body
Food intake, its conversion, and excretion of waste products are material sources 
for the normal functioning of a human body. The aim of nutrition from a biochemical 
viewpoint is to maintain the body’s critical parameters in narrowly defined value rates. 
The concept of a “living healthy organism” consists precisely in the ability to resist 
change and maintain the constancy of the composition and properties of its internal 
environment. The basis of digestion is a fairly universal mechanism, which includes 
splitting of the main components, such as carbohydrates (including polysaccharides), 
fats, biopolymers (proteins, macromolecules based on nucleotide sequences), etc., to 
individual low-molecular substances and then to the synthesis of low- and high-molec-
ular weight compounds, which are the material basis for cells and organs as well as the 
energy source for biochemical reactions. Interest to low-molecular weight compounds 
has grown particularly in recent years. The Human Metabolome Database (HMDB) 
was created and is constantly updated by the international researcher group. Now it 
contains information on more than 100,000 individual low-molecular compounds 
(metabolites), constituting about 25,000 pathways of metabolism [2].
Food digestion is one of the main complex processes that form homeostasis. 
Transformation of the matter occurs throughout the gastrointestinal tract. Food 
undergoes ever-deeper processing as you move through it. Enzymes directly 
involved in this can potentially have endogenous and exogenous origin. The endog-
enous pathway is carried out with the participation of its own secrets produced by 
the body with the participation of organs that promote digestion and the excretion of 
waste products. The complex of biochemical reactions that coincide with the active 
participation of the microbiota, consisting of hundreds, sometimes reaching up to 
several thousand species, is presented as an alternative to it. In the literature there 
is no single point of view about the density of microorganism colonization of the 
human digestive system. According to [3], the relative content of microorganisms 
(cells/mL) in different parts of the gastrointestinal tract is duodenum, 101–103; jeju-
num and ileum, 104–107; cecum, 108; and large intestine, 1011–1012. A large number 
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of publications give the relative content of microorganisms in the range of 102–1013, 
while the maximum values are recorded in the cecum and transverse colon.
The specificity of food digestion is due to the variety of enzymes capable of carry-
ing out similar biochemical transformations, if not entirely, then at least of its many 
components, due to intestinal microbiota. The synthesis of specific proteins, including 
enzymes, is due to the presence of various nucleotide DNA sequences. The diversity 
of these sequences in a complex system consisting of hundreds, or even thousands, of 
individual species of microorganisms is significantly higher than that of human. The 
lifetime of a particular microorganism, depending on the immune response of the host 
organism, correlates with the function that promotes or interferes with its vital activ-
ity. The production of specific microorganism killer proteins is not observed in the case 
of symbiosis. Processes of synthesis of interleukins and phagocytosis are immediately 
activated in the alternative situation [4]. A big array of metagenomic studies of human 
intestinal microbiota collected in recent years in various information repositories, such 
as the National Center for Biotechnology Information (NCBI).
The role of microbiota is quite significant already at the stage of primary processing 
of nutrients. For example, in [5], the fact is given that only bacteroids of the Bacteroides 
thetaiotaomicron contain nucleotide sequences for the synthesis of 260 glycosidic 
hydrolases, while the entire human genome is capable of producing only 17 such 
enzymes, and 9 of them are not fully characterized. The author of the review [6] pro-
vides several specific metabolic pathways associated with intestinal microbiota. These 
include (i) cleavage of polysaccharides to monomers, followed by processing into 
short-chain fatty acids; (ii) depolymerization of proteins to amino acids, with further 
conversion of some of them (glycine, lysine, arginine, leucine, isoleucine, and valine) 
to nitrogen-containing heterocyclic compounds, for example, substituted indoles; (iii) 
neutralization and detoxification of arene-containing components from the external 
environment; and (iv) biotransformation of fats and bile acids and their inclusion in 
biochemical processes that promote energy cells, for example, in the Krebs cycle.
The species composition of the microbiota is specific for each person and depends 
on many factors, such as age, diet, use of antibiotics, etc. We can talk about two com-
ponents of the microbiota—obligate or transient. A self-organizing ecosystem with the 
dominance of some species of microorganisms and the oppression of others arises in a 
normally functioning organism. The classification and systematization of information 
on the species and genetic diversity of the microbiota of the human body were carried 
out independently by two scientific communities in the United States and the European 
Union, which resulted in the appearance of two databases: Human Microbiome Project 
(HMP) [7] and Metagenomics of the Human Intestinal Tract (MetaHIT) [8].
Extensive information on the composition of the intestinal microbiota of a 
healthy person is contained in the literature. These studies indicate the dominance 
of several genera of strict anaerobes, and the main ones are Bacteroides, Prevotella, 
Eubacterium, Ruminococcus, Clostridium, Lactobacillus, and Bifidobacterium. The data 
on the microbial community of the gastrointestinal tract are summarized in detail 
in the 2018 review [9] and presented in Table 1, which reflects the gradual change in 
the species composition of microorganisms as food progresses and digests.
A huge number of types of microorganisms perform the biochemical functions 
which we call the “conveyor” of the microbiota [10]. The diversity of species with 
different biochemical activity provides coordinated work of the microbiota. The 
final metabolite formation depends on many factors: the quality and quantity of 
substrate (food components); the function of the stomach, pancreas, liver, and 
gallbladder; bowel motility; etc. definitely influence the metabolism of microbiota. 
The normal biotransformation of any of the substrates in the intestinal lumen 
takes place sequentially [10]. Biochemistry of deep food transformation is in many 
respects similar to the metabolic characteristic of microorganisms. The main part of 
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the individual amino acids that come from food after the cleavage of polypeptides is 
further spent on the synthesis of its own proteins, which are necessary for the func-
tioning of the body. Residual amino acids can be transformed into other substances 
of a non-protein nature, performing a number of important functions not related to 
digestion or the building function.
This trend is most pronounced for aromatic amino acids such as phenylalanine, 
tyrosine, and tryptophan. The transformations of the phenylalanine-tyrosine pair 
occurring in the liver are contained in the human metabolome database (Figure 3). 
Phenylalanine and tyrosine are interchangeable in terms of metabolism. Phenylalanine 
is transformed into tyrosine under the action of a complex compound of Fe2+ ions with 
phenylalanine-4-hydroxylase with the participation of L-erythrotetrahydrobiopretin. 
Then both amino acids are transformed into 4-hydroxyphenylpyruvic acid, and then, 
by successive transformations, they are transformed into acetoacetic and fumaric 
acids—components of the Krebs cycle under the action of the same enzymes with the 
participation of the same substances [11]. There is no direct conversion of phenylpyru-
vic acid to 4-hydroxyphenylpyruvic acid in this metabolism scheme.
The pathway of tyrosine processing, namely, its biotransformation in tyramine 
further into three directions—dopamine, homovanillin, and dopachinone—is impor-
tant for the normal functioning of human mental activity (Figure 4). All biochemical 
transformations that make up these metabolic pathways occur with the direct action 
of enzymes. However, enzymes for not all reactions are listed in the HMDB. The label 
“??” (Figure 4) refers to the absence of data on the enzyme. The pathway reactions 
can be divided into two types: “traditional” and “unusual.”
The first type is rather trivial transformations, such as the conversion of an 
aldehyde to the corresponding carboxylic acid, for example, homovanillin to 
homovanillic acid. Such transformations are well known in classical organic 
chemistry. These reactions do not require enzymes; it is enough to have an 
oxidizing agent, such as molecular oxygen, hydrogen peroxide, reactive oxygen 
species, etc. The situation is different in the case of the formation of nitrogen-
containing heterocycles formed from aromatic amino acids. The information 
about enzyme in HMDB is not available for the key dopachinone conversion reac-
tion to leukodopachrome. A detailed study of the mechanism of this reaction, 
contained in [12], shows that nitric oxide (I) takes an active part in it. This fact 
is complicated only by understanding the base of interactions. Many reactions of 
Part of the 
gastrointestinal 
tract
The dominant species composition of the microbiota
Oral cavity Gemella, Granulicatella, Streptococcus, Prevotella, Veillonella, Porphyromonas, 
Neisseria, Rothia, Lactobacillus, Fusobacterium
Throat, esophagus Streptococcus, Prevotella, Actinomyces, Gemella, Rothia, Granulicatella, Haemophilus, 
Veillonella
Stomach Helicobacter pylori, Veillonella, Lactobacillus
Small intestine Enterococcus, Escherichia coli, Klebsiella, Lactobacillus, Staphylococcus, Streptococcus, 
Bacteroides fragilis, Clostridium lituseburense, Gammaproteobacterium
Cecum Lactobacillus, Enterococcus, Escherichia coli, Bacteroides, Clostridium leptum, 
Clostridium coccoides
Rising gut Bacteroides, Lactobacillus, Bifidobacterium
Colon Bacteroides, Clostridium, Desulfomonas, Desulfovibrio
Table 1. 
Differences in the composition of the microbiota throughout the gastrointestinal tract (adapted from [9]).
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tyrosine metabolism are supported by a complex of copper ions with tyrosinase, 
well known in the biochemistry of microorganisms and used in biotechnology 
(see, e.g., [13]).
A significant part of the reactions given in Figure 4, with a sufficient degree of 
confidence, occurs with the participation of enzymes of exogenous (microbiologi-
cal) origin generated by the microbiota. The formation of metabolites not only with 
the benzene but also with the indole ring occurs as a result of tyrosine biotransfor-
mation, including the participation of microbial enzymes.
Indoles, including those synthesized using human microbiota enzymes, play an 
important role in metabolism. Such physiologically important substances as sero-
tonin, tryptamine, and derivatives of quinic acid belong to them (Figure 5). Many 
of the compounds involved in the indole metabolism are able to pass through the 
blood–brain barrier. About 95% of tryptophan enters the brain as a conjugate with 
kynurenine compounds, whose final metabolic products are kinuric and quinolinic 
acids, 3-hydroxykynurenine [14].
Reactions associated with the presence of endogenous enzymes and enzymes of 
microbial origin are in a state of dynamic equilibrium with the normal function-
ing of biochemical processes in the body. Microbiota metabolism is able to quickly 
adjust in a direction that helps to maintain homeostasis with moderate deviations 
(abnormalities with dietary errors, travels with changing time zones, etc.). The 
dynamic metabolism of the “invisible organ” is provided by the potential of the 
metabolic pathways, such as catecholamine biosynthesis (Figure 6) with participa-
tion of numerous species of microorganisms.
Microbiota metabolism can also be seriously affected if the disorders are sys-
temic under the influence of adverse external factors (e.g., massive antimicrobial 
therapy, severe poisoning, hypoxia, blood loss, etc.). These disorders can manifest 
themselves clinically by developing a critical state, which often puts the existence of 
the organism (its life) at risk.
Figure 3. 
Normal metabolism of phenylalanine and tyrosine in the liver. Enzymes (coenzymes): (1) phenylalanine-4-
hydroxylase (Fe2+); (2) aspartate aminotransferase, cytoplasmic tyrosine aminotransferase; (3) L-amino-acid 
oxidase (FAD); (4) 4-hydroxyphenylpyruvate dioxygenase (Fe3+); (5) homogentisate 1,2-dioxygenase; (6) 
maleylacetoacetate isomerase; (7) fumarylacetoacetase (according to the HMDB).
7Metabolomic Discovery of Microbiota Dysfunction as the Cause of Pathology
DOI: http://dx.doi.org/10.5772/intechopen.87176
3. Microbiota dysfunction in pathology
3.1 Diseases of the digestive tract
Disturbances in the normal functioning of the gastrointestinal tract are largely 
due to changes in the digestion processes associated with the state of the microbiota. 
As noted above, the microbiota composition depends on the heredity and health 
Figure 4. 
Tyrosine metabolism. Enzymes (coenzymes): (1) aromatic-L-amino-acid decarboxylase, (Pyridoxal-
5′-phosphate); (2) tyrosinase (Cu2+); (3) amiloride-sensitive amine oxidase [copper-containing] (Cu2+, 
Ca2+, topaquinone); (4) dopamine beta-hydroxylase (Cu2+, pyrroloquinoline, quinone); (5) aldehyde 
dehydrogenase (dimeric NADP-preferring); (6) amine oxidase [flavin-containing] A (FAD); (7) aldehyde 
dehydrogenase,(dimeric NADP-preferring); (8) catechol O-methyltransferase (Mg2+) (according to the 
HMDB).
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of the host, climate, nutrition, bad habits, etc. A system itself is able to return to a 
state of homeostasis in the case of mild disorders. The microbiota has mechanisms 
to adapt to the effects of antibacterial substances. Antibiotics are originally the 
products of bacteria which they use as competitive advantage in the conditions 
Figure 5. 
Simplified scheme of normal tryptophan metabolism. Enzymes (coenzymes): (1) tryptophan 
5-hydroxylase (Fe2+); (2) tryptophan 2,3-dioxygenase (heme); (3) aromatic-L-amino-acid decarboxylase 
(pyridoxal-5′-phosphate); (4) indolethylamine N-methyltransferase; (5) kynurenine formamidase; (6) 
kynurenine 3-monooxygenase (FAD); (7) aldehyde dehydrogenase, mitochondrial (NAD); (8) aldehyde 
dehydrogenase, mitochondrial or aldehyde oxidase (FAD, molybdopterin, 2Fe-2S); (9) kynureninase 
(pyrophosphate); (10) acetylserotonin O-methyltransferase (S-Adenosyl methionine) (according to the 
HMDB).
Figure 6. 
Catecholamine biosynthesis. Enzymes (coenzymes): (1) tyrosine 3-monooxygenase (Fe2+); (2) aromatic-L-
amino-acid decarboxylase (pyridoxal-5′-phosphate); (3) dopamine beta-hydroxylase (Cu2+, pyrroloquinoline, 
quinone); (4) phenylethanolamine N-methyltransferase) (according to the HMDB).
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of nutrient substrate deficiency in their habitat. However, significant changes in 
species composition may be developed under the influence of broad-spectrum 
antibacterial drugs, since the massive use of antibiotics (xenobiotics) is violent and 
anti-biological and can disrupt biochemical processes.
The microbiota is involved in the transformation of xenobiotics and provides 
a range of reactions including acetylation, deacylation, decarboxylation, dehy-
droxylation, demethylation, etc. under the influence of low-quality products and 
synthetic drugs [15]. Modern possibilities of metabolic methods allow an extensive 
study of another important function of the microbiota—detoxification of the host 
organism, which maintains its normal state longer in the conditions of retention 
and self-repairing of the microbiota.
Disorders of the microbial products of short-chain fatty acids SCFA (acetic, 
propionic, butyric) are most thoroughly studied as a result of the suppression of the 
normal functioning of anaerobic bacteria. Normally, SCFA requires enterocytes as 
the main source of energy, respectively; their deficiency contributes to the violation 
of mucosal trophism, reduction of reparative processes, development of ulcers, 
and inflammation. Persistent indigestion disorders and chronic gastroenterological 
diseases are the clinical manifestations of serious changes in the species composi-
tion and dysfunction of the microbiota.
Different genera of anaerobic bacteria are called responsible for the production of 
SCFA. For example, large amount of carbohydrate dissimilation butyrate from dissimi-
lation is associated with some Clostridia clusters, other SCFAs, and Bifidobacterium spp.
In his review, Nyangale et al. rightly noted that several members of the micro-
biota have been linked with diseases mainly affecting the gut, lake inflammatory 
bowel disease, such as ulcerative colitis, Crohn’s disease, colorectal cancer, and 
irritable bowel syndrome, although mechanisms involved are still not yet fully 
understood [16]. The authors consider the possibilities of metabolite analysis to 
assess the metabolic activity of the microbiota, to measure volatile and nonvolatile 
metabolite in biological samples, and to give metabolic pathways the contribu-
tion of microbiota to which it is most pronounced. These pathways include also 
the transformation of glucose and amino acids into SCFA, amino acid, microbial 
degradation of tyrosine to p-hydroxyphenylacetic and p-hydroxyphenylbenzoic 
acids (including bypassing tyramine), and degradation of tryptophan to indolepro-
pionate and indoleacetate (including bypassing tryptamine).
A metabolite composition, determined in the feces, may indicate the composi-
tion of microbiota and its changes associated with the use of antibiotics [17]. The 
use of chemometric approaches in relation to the primary mass spectral data of the 
samples under study allows one to reliably find the differences between patients 
with inflamed intestines and the control group. The authors consider that changes 
in the microbiota phenotype cause this kind of deviations. The ratio of the spe-
cies composition of microbiota—obligate or transient—significantly affects the 
metabolite composition that enters the circulatory system from the bowel. Thus, the 
role of Bacillus and Lactobacillus, colonizing the epithelium of the gastrointestinal 
tract, is systematically examined in a review of Ilinskaya et al. [18]. The metabolite 
composition depends significantly on the activity of their enzymatic systems, even 
with a relatively low content of such microorganisms in the microbiota.
In such acquired endocrinological diseases as obesity, type 2 diabetes (not 
related to heredity) can be attributed to pathological conditions due to metabolic 
disorders involving the microbiota. Microbiota can influence the development 
of diabetes [19]. Changes in the microbiological composition—dysbacteriosis—
caused, for example, by the use of antibiotics, may contribute to an increase in 
insulin dysfunction, a long-term consequence of which is the development of type 2 
diabetes. Due diet may ensure opportune correction of the microbiota and prevent 
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further development of the disease. In a similar study for type 2 diabetes, cited in 
[20], the authors come to analogous conclusions. The authors agree that function 
is more important than taxonomy when discussing the role of microbiota in the 
development of metabolic disorders and diseases of the gastrointestinal tract [21].
In the future, methods of diagnosing gastrointestinal diseases and methods of 
treatment through the modulation of the microbiota based on information about 
intermediate metabolites and end products of microbial biodegradation of various 
compounds can be constructed and developed.
3.2 Microbial metabolites in oncology
Changes in the human body due to microbiota metabolism can affect cells and 
tissues and contribute to the development of benign and malignant tumors. The 
biochemistry and physiology of oncological processes is not completely clear, but 
certain metabolic shifts can be fixed instrumentally for some types of oncological 
diseases [22, 23]. The successful search for links between the patterns of normal 
functioning of the microbiota and the biochemistry of carcinogenesis is detailed in 
recent reviews [24, 25]. This indicates the prospects of such concept and allows us to 
call the microbiota “a key orchestrator of cancer therapy.”
Most of the data on the correlation between a microbiota and cancer tumors is in the 
gastroenterology [26–31]. Such intestinal microorganisms as Fusobacterium nucleatum, 
Streptococcus gallolyticus, Bacteroides fragilis, Escherichia coli, and Enterococcus faecalis 
are most often mentioned as potential participants of the process. The inflammatory 
process in the epithelium or deeper tissues of the intestinal wall leads to increased 
local blood supply. At the same time, a favorable substrate is created for the massive 
multiplication of bacteria, the formation of microbial biofilms, which contributes to the 
activation of the enzymatic systems of bacteria, increasing concentrations of potentially 
dangerous mutagenic products of microbial metabolism. According to [30], the highest 
specificity of microorganisms contributing to the occurrence of colorectal cancer is 
noted in streptococci such as Streptococcus bovis and Streptococcus gallolyticus. Other 
authors indicate a violation of homeostasis in the intestine and emphasize the role of 
Lactobacillus deficiency in reducing the protective mechanisms [28].
The analysis of statistical data shows that there is an activation of the biosynthe-
sis of fatty acids against the background of inhibition of the biosynthesis of amino 
acids and glycan in patients with colorectal cancer compared with the control group 
[26]. Statistically significant differences in the levels of metabolites of microbial 
origin, namely, an increase in the relative concentrations of phenylacetic, isobu-
tyric, valeric, isovaleric acids, and hexose-phosphates with a simultaneous decrease 
in taurine, glutamine, β-alanine, isoleucine, galactose, xylose, glycerol, methanol, 
ornithine, guanidine, choline acid, and its derivatives, 4-aminohippuric acid, have 
been identified in a recent paper [32].
Certainty is not currently attainable regarding the use of volatile fatty acids as 
markers of oncology. Reducing the levels of SCFA (acetic, butyric), secondary bile 
acids, concomitant increase in amino acids (leucine, valine, proline, serine) valeric, 
isobutyric, isovaleric acid can be associated with the activity of enzymatic systems 
of Ruminococcus spp., Fusobacterium, Porphyromonas, Clostridia, Lachnospiraceae. 
Changes in the composition of the microbiota in patients with colorectal cancer, 
noted by the authors of the review [31], can be used as a diagnostic method. Also, the 
review authors [33] propose to use the following compound profile: short-chain fatty 
acids (mainly butyric acid), cholium-kilot on deoxycholic acid derivatives, bacterial 
toxin fragilis, and trimethylamine-N-oxide for the diagnosis of colorectal cancer. 
Other authors [34] also suggest a bacterial metabolite butyric acid as a marker for 
colorectal cancer.
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An alternative concept is that volatile fatty acids, for example, butyric acid, 
may have a protective effect, which slows down the development of large intestine 
malignancies. Butyrate-producing bacteria contained in the microbiota of the 
gastrointestinal tract, such as Faecalibacterium prausnitzii, Eubacterium rectale, or 
Roseburia, promote an increase in the content of butyric acid [35].
A treatment of large amounts of information on substances of bacterial origin 
potentially capable of being included in human metabolism allows us to distinguish 
six groups of compounds, based on the profile of which early diagnosis of colorec-
tal cancer can be built [29]. There are short-chain fatty acids, bile acids, indoles, 
cresols, phenolic (phenyl-containing fatty) acids, and polyamines. Analysis of 
literature data [27] shows that under the influence of microbiota, changes in the 
directions of chemical transformation of glucose, fats, and amino acids are possible.
The metabolic profile, largely formed by the microbiota, was used as a diagnos-
tic method for cancer not directly related to the gastrointestinal tract. Statistically 
significant differences in the content of substances involved in the metabolism of 
glycerol lipids and retinol and ways of ethylbenzene degradation can be used to 
diagnose bladder cancer. Such metabolites are actively produced and/or absorbed 
with the participation of enzymes of Herbaspirillum, Gemella, Bacteroides, 
Porphyrobacter, Faecalibacterium, Aeromonas, and Marmoricola [36].
A change in the metabolic profile of amino acids such as valine, cysteine, 
tyrosine, and 6-hydroxynicotinic acid can be used as a method for diagnosing oral 
cancer [37]. Substances of microbial origin and components of the metabolism 
of Helicobacter pylori have a significant impact on the formation and growth of 
malignant neoplasms of the esophagus, large intestine, pancreas, and lung. A cross-
sectional statistical analysis shows that the likelihood of oncological complications 
associated with Helicobacter pylori increases in smokers and patients diagnosed with 
chronic pancreatitis and diabetes [38].
The metabolites produced by the microbiota of the upper respiratory tract and 
lungs may influence the development of oncological processes in them. Three types 
of bacteria, Granulicatella, Streptococcus, and Veillonella, are mentioned most often 
in this connection. They probably have differences in the metabolism of poly-
amines, expressed in elevated levels of putrescine and similar products. According 
to other data, dysbiosis and an increase in Streptococcus and Mycobacterium are 
practically not associated with the development of lung cancer [39].
However, waste products of bacteria can contribute to the development of breast 
cancer [22, 40–42]. The waste products of bacteria of the gastrointestinal tract can 
contribute to the development of malignant tumors of any other location: lung 
cancer [38, 39], bladder [36], pancreas [38], including hormone-dependent forms 
of breast cancer [22, 38, 40–42], and prostate cancer [43].
Statistically significant correlations between the levels of secondary bile acids and 
the incidence of breast cancer were found in [22]. The authors believe that lithocho-
lic acid, which is a product of the metabolism of microorganisms, is able to limit the 
proliferation of breast cancer cells both in vitro and in vivo by activating the TGR5 
receptor. Changes in the metabolism of hormones, cysteine, and methionine and the 
biosynthesis of fatty acids associated with breast cancer were noted in a similar study 
[41], but there is no definite connection between them. The search for low-molecular 
markers of breast cancer, carried out in [42], allowed identification of 12 compounds 
(amino acids, organic acids, and nucleosides) that pretend to this role. These com-
pounds are included in the metabolism of amino acid and nucleoside metabolism.
Microbiota metabolites are able to act as accelerants and inhibitors of oncological 
processes. Now a scientific search in this field of knowledge is in the stage of intensive 
development and accumulation of a critical amount of information. The use of metab-
olomic approaches in combination with modern methods of statistical processing of 
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large amounts of data undoubtedly contributes to the development of fundamental 
and applied medicine in the field of diagnosis and treatment of oncological diseases.
3.3 Neurological pathology and mental disorders
Some substances that form the amino acid metabolism can overcome the hemato-
encephalic barrier and have a direct effect on the brain (Figure 7) [14, 44–46].  
A search for such low-molecular compounds, quantitative determination, and their 
ratios can serve as the basis for the development of methods for early diagnosis, 
including cognitive and mental disorders [47]. It is important to note that metabolites 
can directly enter the region of the medulla, with blood through arteria vertebralis-
arteria spinalis, bypassing the hemato-encephalic barrier, and that critical vital 
centers of respiration and circulation are located there.
It is unlikely that metabolites of microbial biotransformation of amino acids are 
the direct cause of mental or neurological diseases. At the same time, numerous 
experimental studies indicate the existence of a direct “intestine-microbiota-brain” 
link. Current evidence suggests that multiple mechanisms, including endocrine and 
neurocrine pathways, may be involved in gut microbiota-to-brain signaling and that 
the brain can in turn alter microbial composition and behavior via the autonomic 
nervous system [48].
The authors in literature sources traditionally attend to the aromatic amino 
acid tryptophan metabolism mainly due to its relationship with the synthesis of 
serotonin (5-HT) and melatonin [49]. Tryptophan biotransformation in humans 
can occur in different ways: either with the participation of endogenous enzymes 
that are synthesized by the intestinal cell wall or with the participation of bacterial 
enzymes. Accordingly, the ratios of end products of tryptophan metabolism will 
differ. This is easily seen by comparing the enzymes and metabolic products of 
tryptophan in Figures 5 and 8.
The traditional view is that the amino acid tryptophan is used primarily for 
protein synthesis or the formation of serotonin and melatonin. However, more than 
90% of tryptophan was found to be metabolized into N-formyl-kynurenine fol-
lowed by kynurenine (Figure 8) [50]. The presence of anthranilic and 3-hydroxy-
anthranilic acids attracts particular attention as tryptophan metabolites. This 
pathway is not presented in mammalian metabolism. Such reactions of indole 
compounds are possible only with the participation of microbiota enzymatic 
systems. This also applies to picolinic and quinolinic acids, the formation of which 
Figure 7. 
Scheme of amino acid metabolite transport in the brain.
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is associated with the opening of the indole ring, which can occur exclusively in the 
process of microbial biotransformation.
A decrease of tryptophan, xanthurenic, 3-hydroxyanthranilic, and quinolinic 
acids in the blood was recorded in the case of clinical occurrences of Alzheimer’s 
disease. The same metabolites are given in [51] as potential markers of Alzheimer’s 
disease. It can be assumed that one of the Alzheimer’s disease triggers is a chronic 
deficiency of these substances.
Now there are two alternative hypotheses in the literature regarding products of 
tryptophan metabolism and their influence on the development of schizophrenia. 
One of them postulates that a chronic tryptophan deficiency results in failure of 
catabolism products, such as 3-hydroxykynurenine, quinolinic, picolinic, xanth-
urenic, kinureric, and anthranilic acids. Some authors maintain that such deficiency 
stipulates the psychosomatic symptoms of schizophrenia [52]. Other authors 
come to the opposite conclusion based on the analysis of statistical data [53]. They 
indicate a direct correlation of clinical manifestations of schizophrenia with an 
increased content of kynurenic acid in the cerebrospinal fluid relative to the control 
group. Such conflicting data emphasize once again the peculiarities of the metabolic 
approach. You should not limit yourself to searching and measuring one or two 
metabolites during clinical trials; it is important to evaluate the complex metabolic 
profile, to compare the indicators with positive and negative dynamics. In addition, 
other mechanisms that are not related to the metabolism of neurotransmitters may 
be the basis of mental and neurologic disorders.
Thus, attempts to search for low-molecular markers of autism [54] and depres-
sive disorder [55] were unsuccessful. But the data indicating the potential role of 
the metabolism of aromatic amino acids were discovered in such a mental disorder 
as anorexia nervosa. Levels of tryptophan and phenylalanine were significantly 
reduced in patients compared with the healthy ones.
Changes in the distribution of the tryptophan metabolism products, such as 
kynurenine, 3-hydroxy kynurenine, kynurenic, and anthranilic acids, are observed 
Figure 8. 
Tryptophan metabolism. Enzymes: (1) indoleamine deoxygenase or tryptophan deoxygenase; (2) formidase; 
(3) kynurenine aminotransferase; (4) kynureninase; (5) kynurenine-3-monooxygenase; (6) kynureninase; (7) 
3- hydroxyanthranilate 3,4-dioxygenase; (8) 2-amino-3- carboxymuconate-semialdehyde decarboxylase (according 
to [50]).
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in patients with symptoms of Parkinson’s disease [56]. Low levels of norepineph-
rine, dopamine, homovanillic acid, serotonin, and 5-hydroxyindoleacetic acid in the 
blood are fixed in these patients relative to the control group [57].
The failure of aromatic L-amino acid decarboxylase in combination with reduced 
levels of important metabolites such as serotonin, dopamine, and catecholamines 
leads to disruptions in the normal functioning of the whole organism, including brain 
activity. Crisis of oculomotor function along with muscular hypotonia and dystonia is 
observed in combination with other neurological syndromes in a similar state [58]. A 
decrease in the blood concentrations of homovanillic, 5-hydroxyindoleacetic acids, and 
3-o-methyldopamine—substances included in the metabolism of tyrosine (Figure 4)—
was observed in all patients. It can be noted with a high assurance that the deficiency of 
these metabolites is due to the lack of the transformation enzymes responsible for these 
reactions of the aromatic amino acids usually found in the microbiota.
3.4 Prospects for neurorehabilitation
Scientists have used metabolomics to gain new knowledge about the significance 
of the role that bacteria play in complex regulatory processes of higher nervous activ-
ity. Understanding the potential for managing this process cannot leave psychiatrists, 
neurologists, and neurorehabilitation specialists indifferent [59–61]. This fact is due 
to the relevance and high frequency of pathology of the nervous system. Prospects for 
the correction of microbiota metabolism for neurorehabilitation and the demand for 
this scientific search for new solutions in this area cannot be overestimated.
One of the areas discussed in the literature is the transformation of the species 
composition of the patient’s microbiota to eliminate the deficiency of certain micro-
organisms. This idea has a scientific ground that many bacteria from the human 
microbiota in the in vitro study revealed the ability to produce hormones and 
neurotransmitters, that is, the presence of appropriate enzyme systems. These data 
are summarized in the reviews [44, 62] and in brief form are presented in Table 2.
Certain reports indicate that the treatment with large doses of Lactobacillus casei 
has a positive effect. Patients with chronic fatigue syndrome reported a decreased 
strain (n = 39). Patients who took a probiotic reported a significant decrease in 
symptoms of anxiety and had a substantial increase in the number of Lactobacillus 
and Bifidobacteria compared with the control group (p = 0.01). [63]. At the same 
time, treatment with live microorganisms (including fecal microbiota transplanta-
tion, FMT) is hardly predictable and can have negative consequences due to the 
variability of bacterial metabolism depending on the environment. For example, a 
randomized, double-blind, controlled study on the use of a drug based on lactoba-
cilli in combination with prebiotic gives a negative result in patients with pancreatic 
necrosis: the mortality rate in the group receiving the biological product was 
significantly higher than in the control [64].
Neurorehabilitation of patients in modern clinics is considered as a component 
of acute cerebral therapy and starts from the earliest periods after injuries, strokes, 
and brain operations, even at the stage of the patient’s stay in the intensive care 
unit. This is a multicomponent and long-term process aimed not only at saving lives 
but also at restoring motor activity, correcting neuro-endocrine, cognitive impair-
ments, and emotional status. Different methods of monitoring the effectiveness of 
intensive care and the rehabilitation of the functional state of patients with various 
brain injuries are used [65].
The authors of this chapter believe that neurorehabilitation can be significantly 
enriched with a set of targeted measures aimed at correcting disorders in the 
development of which metabolic products associated with microbiota are actively 
involved. Our accumulated data on the magnitude of changes in the profile of 
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microbiota metabolites and their connection with the course and outcome of the 
disease in patients with lesions of the central nervous system indicate the possibil-
ity of their use in choosing tactics for managing patients with this pathology. This 
complex may include several areas: (i) the first is the additional introduction into 
the body of substances that are associated with a shortage of other clinical mani-
festations of pathology. This can be achieved by nutritional correction or dietary 
supplements, including those obtained using industrial microbiology methods, 
as well as the administration of parenteral preparations containing the necessary 
metabolites of microbial origin. (ii) The second is the suppression of the metabolic 
activity of those types of bacteria in the composition of the microbiota, which in 
excess produce “unwanted” metabolites, through the selective use of antibacterial 
drugs with an appropriate mechanism of action. (iii) The third is the elimination of 
excess unwanted metabolites in the systemic circulation through the targeted use 
of extracorporeal blood purification procedures with filters/sorbents that remove 
specific substances.
Of course, the use of modern metabolic methods for an objective assessment 
of the dynamics of the profile of metabolites in parallel with the monitoring of the 
psychosomatic state, functions of the damaged brain, spasticity level, motor skills, etc. 
is necessary for the successful implementation of the above directions in a particular 
patient. But above all, reliable data on key microbial metabolites, the level of which 
must be monitored in patients in the process of neurorehabilitation to on must be 
obtained. For example, metabolites associated with the development of septic shock 
(p-HPhAA) [66, 67] and death (PhA, p-HPhLA) [10] were earlier established for 
patients with sepsis. At the same time, another metabolite—PhPA—was a characteris-
tic for the metabolic profile of a healthy person. The study of metabolome is conducted 
using the GC–MS method for patients with affection of the central nervous system 
of various etiologies [68]. Currently, the purpose of this study is to detect microbial 
metabolites associated with changes in the neurological status of patients in the process 
of neurorehabilitation. Preliminary results indicate a number of significant features, 
Hormone, 
neurotransmitter
Bacteria
Norepinephrine Bacillus subtilis, Bacillus mycoides, Proteus vulgaris, Serratia marcescens
Dopamine B. subtilis, B. mycoides, Bacillus cereus, Staphylococcus aureus, P. vulgaris, S. 
marcescens, Escherichia coli, Morganella morganii, Klebsiella pneumonia, Hafnia 
alvei, Lactobacillus helveticus, Lactobacillus delbrueckii subsp. bulgaricus
Dopamine precursor 
(DOPA)
E. coli, B. cereus, L. helveticus, L. casei, L. delbrueckii subsp. bulgaricus, Toxoplasma 
gondii
Serotonin S. aureus, Enterococcus faecalis, Rhodospirillum rubrum, B. subtilis, E. coli, M. 
morganii, K. pneumonia, H. alvei, Lactococcus lactis subsp. cremoris, L. lactis subsp. 
lactis, Lactococcus plantarum, L. helveticus
Histamine M. morganii, P. vulgaris, Proteus mirabilis, Klebsiella sp., Enterobacter aerogenes, 
E. cloacae, Citrobacter freundii, Enterobacter amnigenus, Vibrio alginolyticus, 
Acinetobacter lowfli, Pseudomonas fluorescens, P. putida, Aeromonas spp., Clostridium 
spp., Photobacterium spp., Lactobacillus buchneri, Streptococcus thermophilus
γ-Aminobutyric acid Bifidobacterium adolescentis, B. dentium, B. infantis, B. angulatum, Lactobacillus 
brevis, L. plantarum, L. paracasei, L. buchneri, L. helveticus, L. delbrueckii, L. 
reuteri, L. zymae
Tyramine Lactobacillus spp., Lactococcus spp., Enterococcus spp., Carnobacterium
Table 2. 
Literary data on the ability of many bacteria: representatives of the human microbiota to participate in the 
production of hormones and neurotransmitters (adapted from [44, 62]).
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for example, positive neurological and psychosomatic dynamics is associated with 
the appearance and accumulation of the metabolite p-HBA in the intestine and the 
patient’s blood, which is not observed in other groups of patients. The composition of 
the microbiota in patients with severe neurosomatic pathology using the method of 
metagenomic sequencing of the 16S pRNA is under study. Correlations with microbial 
blood metabolites are also being studied. Preliminary data demonstrate significant 
differences when comparing various patient groups [69]. The results of the multicenter 
study will serve as the basis for the development and objective evaluation of the 
effectiveness of the above technologies in the process of neurorehabilitation.
4. Conclusion
A new level of knowledge about the role of the microbiota in the human body 
was made possible by metabolomics. In the coming years, this will lead to new 
solutions in the diagnosis of many “difficult” diseases. Methods of active control of 
metabolic processes that will subordinate the dysfunction of the “invisible organ” to 
the benefit of the host will be found. It will lead to the increase in the effectiveness 
of treatment and successful rehabilitation of patients. In particular, in the field of 
neurorehabilitation, clinical studies are currently aimed at finding such methods for 
correcting the metabolism of microbiota that will achieve a balance of low-molecu-
lar metabolites as signaling molecules of microbiota to restore brain function.
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